Brief: Sellas Life Sciences' Committee Recommends Galinpepimut-S Regal Trial To Continue As Planned
08/12/2022 15:47
Dec 8 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS LIFE SCIENCES’ INDEPENDENT DATA MONITORING
COMMITTEE
RECOMMENDS GALINPEPIMUT-S REGAL TRIAL TO CONTINUE AS PLANNED
Source text for Eikon: ID:nGNX7DkTrx
Further company coverage: SLS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses